New algorithm is offered on Siemens’ SOMATOM Force CT system.
The U.S. Food and Drug Administration (FDA) has given 510(k) clearance for a new image reconstruction algorithm for CT developed by Siemens.
The Advanced Model Iterative Reconstruction (ADMIRE) supplements Siemens’ Sinogram Affirmed Iterative Reconstruction (SAFIRE), which is a raw-data based iterative reconstruction algorithm that can provide dose reduction of up to 60 percent, according to a release. Siemens states that image quality, which usually tends to worsen with lower dose, can result in images with a natural image impression and improved reconstructed image quality with ADMIRE.[[{"type":"media","view_mode":"media_crop","fid":"27102","attributes":{"alt":"","class":"media-image media-image-right","id":"media_crop_8598634534260","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"2604","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","style":"height: 66px; width: 100px; border-width: 0px; border-style: solid; margin: 1px; float: right;","title":" ","typeof":"foaf:Image"}}]]
ADMIRE is offered in Siemens’ SOMATOM Force, a dual-source CT system, and uses additional modeling loops that help deliver improved resolution at high contrast edges, resulting in the ability to deliver many studies at previously unachievable low-dose imaging, the release said.
What Emerging CT Research Reveals About Obesity and Post-Op Survival for Non-Small Cell Lung Cancer
January 29th 2025For those without low skeletal muscle mass on CT and myosteatosis, obese patients have a 23 percent lower risk of death than non-obese patients after undergoing curative resection for non-small cell lung cancer, according to newly published research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.